Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by toinv261on Aug 08, 2016 4:48pm

93 Views

Post# 25120614

RE:RE:FTHX HEARTLAND /MY SENTIMENTS EXCATLY

Hi GV.

I don't disagree that Don has been able to bring in the investments and these investments come because of Dr Wong and the science. I believe Don should receive a base pay of say $150,000 plus benefits but have a huge options package at critical points such as the futility phase of BETonMACE ph lll or completion of the next regional deal or confirmation of future financing.

Don does not deserve his current compensation although since he controls the Board he controls his pay!

It is unfortunate but Stockhouse has become unstable again. I tried to post a number of times on the weekend but failed.
GLTA
Toinv

Bullboard Posts

Bombardier delivers Global 6500 aircraft to U.S. Army